Ki-67 gene expression.
Journal
Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
09
08
2020
accepted:
16
06
2021
revised:
13
06
2021
pubmed:
30
6
2021
medline:
23
3
2022
entrez:
29
6
2021
Statut:
ppublish
Résumé
Ki-67 serves as a prominent cancer marker. We describe how expression of the MKI67 gene coding for Ki-67 is controlled during the cell cycle. MKI67 mRNA and Ki-67 protein are maximally expressed in G
Identifiants
pubmed: 34183782
doi: 10.1038/s41418-021-00823-x
pii: 10.1038/s41418-021-00823-x
pmc: PMC8629999
doi:
Substances chimiques
Biomarkers, Tumor
0
Ki-67 Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3357-3370Subventions
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : 424870812
Informations de copyright
© 2021. The Author(s).
Références
Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31:13–20.
pubmed: 6339421
doi: 10.1002/ijc.2910310104
Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.
pubmed: 10653597
doi: 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 1991;138:867–73.
pubmed: 2012175
pmcid: 1886092
Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710–5.
pubmed: 6206131
doi: 10.4049/jimmunol.133.4.1710
Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res. 2008;14:8019–26.
pubmed: 19088018
doi: 10.1158/1078-0432.CCR-08-0974
Booth DG, Takagi M, Sanchez-Pulido L, Petfalski E, Vargiu G, Samejima K, et al. Ki-67 is a PP1-interacting protein that organises the mitotic chromosome periphery. Elife 2014;3:e01641.
pubmed: 24867636
pmcid: 4032110
doi: 10.7554/eLife.01641
Cuylen S, Blaukopf C, Politi AZ, Muller-Reichert T, Neumann B, Poser I, et al. Ki-67 acts as a biological surfactant to disperse mitotic chromosomes. Nature 2016;535:308–12.
pubmed: 27362226
pmcid: 4947524
doi: 10.1038/nature18610
Sobecki M, Mrouj K, Camasses A, Parisis N, Nicolas E, Lleres D, et al. The cell proliferation antigen Ki-67 organises heterochromatin. Elife 2016;5:e13722.
pubmed: 26949251
pmcid: 4841783
doi: 10.7554/eLife.13722
Cuylen-Haering S, Petrovic M, Hernandez-Armendariz A, Schneider MWG, Samwer M, Blaukopf C, et al. Chromosome clustering by Ki-67 excludes cytoplasm during nuclear assembly. Nature 2020;587:285–90.
pubmed: 32879492
pmcid: 7666080
doi: 10.1038/s41586-020-2672-3
Sun X, Bizhanova A, Matheson TD, Yu J, Zhu LJ, Kaufman PD. Ki-67 contributes to normal cell cycle progression and inactive X heterochromatin in p21 checkpoint-proficient human cells. Mol Cell Biol. 2017;37:e00569-16.
Mrouj K, Andres-Sanchez N, Dubra G, Singh P, Sobecki M, Chahar D, et al. Ki-67 regulates global gene expression and promotes sequential stages of carcinogenesis. Proc Natl Acad Sci USA. 2021;118:e2026507118.
Sobecki M, Mrouj K, Colinge J, Gerbe F, Jay P, Krasinska L, et al. Cell-cycle regulation accounts for variability in Ki-67 expression levels. Cancer Res. 2017;77:2722–34.
pubmed: 28283655
doi: 10.1158/0008-5472.CAN-16-0707
Gerlach C, Sakkab DY, Scholzen T, Dassler R, Alison MR, Gerdes J. Ki-67 expression during rat liver regeneration after partial hepatectomy. Hepatology 1997;26:573–8.
pubmed: 9303485
doi: 10.1002/hep.510260307
Schmidt MH, Broll R, Bruch HP, Finniss S, Bogler O, Duchrow M. Proliferation marker pKi-67 occurs in different isoforms with various cellular effects. J Cell Biochem. 2004;91:1280–92.
pubmed: 15048881
doi: 10.1002/jcb.20016
Ishida S, Huang E, Zuzan H, Spang R, Leone G, West M, et al. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol. 2001;21:4684–99.
pubmed: 11416145
pmcid: 87143
doi: 10.1128/MCB.21.14.4684-4699.2001
Tian H, Qian GW, Li W, Chen FF, Di JH, Zhang BF, et al. A critical role of Sp1 transcription factor in regulating the human Ki-67 gene expression. Tumour Biol. 2011;32:273–83.
pubmed: 20963645
doi: 10.1007/s13277-010-0119-4
Fischer M, Steiner L, Engeland K. The transcription factor p53: Not a repressor, solely an activator. Cell Cycle. 2014;13:3037–58.
pubmed: 25486564
pmcid: 4612452
doi: 10.4161/15384101.2014.949083
Fischer M, Quaas M, Steiner L, Engeland K. The p53-p21-DREAM-CDE/CHR pathway regulates G2/M cell cycle genes. Nucleic Acids Res. 2016;44:164–74.
pubmed: 26384566
doi: 10.1093/nar/gkv927
Engeland K. Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM. Cell Death Differ. 2018;25:114–32.
pubmed: 29125603
doi: 10.1038/cdd.2017.172
Müller GA, Quaas M, Schümann M, Krause E, Padi M, Fischer M, et al. The CHR promoter element controls cell cycle-dependent gene transcription and binds the DREAM and MMB complexes. Nucleic Acids Res. 2012;40:1561–78.
pubmed: 22064854
doi: 10.1093/nar/gkr793
Müller GA, Engeland K. The central role of CDE/CHR promoter elements in the regulation of cell cycle-dependent gene transcription. FEBS J. 2010;277:877–93.
pubmed: 20015071
doi: 10.1111/j.1742-4658.2009.07508.x
Sadasivam S, DeCaprio JA. The DREAM complex: master coordinator of cell cycle-dependent gene expression. Nat Rev Cancer. 2013;13:585–95.
pubmed: 23842645
pmcid: 3986830
doi: 10.1038/nrc3556
Müller GA, Wintsche A, Stangner K, Prohaska SJ, Stadler PF, Engeland K. The CHR site: definition and genome-wide identification of a cell cycle transcriptional element. Nucleic Acids Res. 2014;42:10331–50.
pubmed: 25106871
pmcid: 4176359
doi: 10.1093/nar/gku696
Litovchick L, Sadasivam S, Florens L, Zhu X, Swanson SK, Velmurugan S, et al. Evolutionarily conserved multisubunit RBL2/p130 and E2F4 protein complex represses human cell cycle-dependent genes in quiescence. Mol Cell. 2007;26:539–51.
pubmed: 17531812
doi: 10.1016/j.molcel.2007.04.015
Dyson NJ. RB1: a prototype tumor suppressor and an enigma. Genes Dev. 2016;30:1492–502.
pubmed: 27401552
pmcid: 4949322
doi: 10.1101/gad.282145.116
Schmit F, Korenjak M, Mannefeld M, Schmitt K, Franke C, von Eyss B, et al. LINC, a human complex that is related to pRB-containing complexes in invertebrates regulates the expression of G2/M genes. Cell Cycle. 2007;6:1903–13.
pubmed: 17671431
doi: 10.4161/cc.6.15.4512
Sadasivam S, Duan S, DeCaprio JA. The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression. Genes Dev. 2012;26:474–89.
pubmed: 22391450
pmcid: 3305985
doi: 10.1101/gad.181933.111
Down CF, Millour J, Lam EW, Watson RJ. Binding of FoxM1 to G2/M gene promoters is dependent upon B-Myb. Biochim Biophys Acta. 2012;1819:855–62.
pubmed: 22513242
doi: 10.1016/j.bbagrm.2012.03.008
Chen X, Müller GA, Quaas M, Fischer M, Han N, Stutchbury B, et al. The forkhead transcription factor FOXM1 controls cell cycle-dependent gene expression through an atypical chromatin binding mechanism. Mol Cell Biol. 2013;33:227–36.
pubmed: 23109430
pmcid: 3554121
doi: 10.1128/MCB.00881-12
Fischer M, Müller GA. Cell cycle transcription control: DREAM/MuvB and RB-E2F complexes. Crit Rev Biochem Mol Biol. 2017;52:638–62.
pubmed: 28799433
doi: 10.1080/10409238.2017.1360836
Quaas M, Müller GA, Engeland K. p53 can repress transcription of cell cycle genes through a p21(WAF1/CIP1)-dependent switch from MMB to DREAM protein complex binding at CHR promoter elements. Cell Cycle. 2012;11:4661–72.
pubmed: 23187802
pmcid: 3562311
doi: 10.4161/cc.22917
Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497–501.
pubmed: 9822382
doi: 10.1126/science.282.5393.1497
Mages CF, Wintsche A, Bernhart SH, Müller GA. The DREAM complex through its subunit Lin37 cooperates with Rb to initiate quiescence. Elife 2017;6:e26876.
pubmed: 28920576
pmcid: 5602299
doi: 10.7554/eLife.26876
Uxa S, Bernhart SH, Mages CFS, Fischer M, Kohler R, Hoffmann S, et al. DREAM and RB cooperate to induce gene repression and cell-cycle arrest in response to p53 activation. Nucleic Acids Res. 2019;47:9087–103.
pubmed: 31400114
pmcid: 6753476
doi: 10.1093/nar/gkz635
Drexler HG, Uphoff CC. Mycoplasma contamination of cell cultures: Incidence, sources, effects, detection, elimination, prevention. Cytotechnology 2002;39:75–90.
pubmed: 19003295
pmcid: 3463982
doi: 10.1023/A:1022913015916
Haeussler M, Zweig AS, Tyner C, Speir ML, Rosenbloom KR, Raney BJ, et al. The UCSC Genome Browser database: 2019 update. Nucleic Acids Res. 2019;47:D853–D8.
pubmed: 30407534
doi: 10.1093/nar/gky1095
Consortium EP, Moore JE, Purcaro MJ, Pratt HE, Epstein CB, Shoresh N, et al. Expanded encyclopaedias of DNA elements in the human and mouse genomes. Nature 2020;583:699–710.
doi: 10.1038/s41586-020-2493-4
Krause K, Wasner M, Reinhard W, Haugwitz U, Lange-zu Dohna C, Mössner J, et al. The tumour suppressor protein p53 can repress transcription of cyclin B. Nucleic Acids Res. 2000;28:4410–8.
pubmed: 11071927
pmcid: 113869
doi: 10.1093/nar/28.22.4410
Müller GA, Stangner K, Schmitt T, Wintsche A, Engeland K. Timing of transcription during the cell cycle: protein complexes binding to E2F, E2F/CLE, CDE/CHR, or CHR promoter elements define early and late cell cycle gene expression. Oncotarget. 2016;8:97736–48.
pubmed: 29228647
pmcid: 5716687
doi: 10.18632/oncotarget.10888
Qin XQ, Chittenden T, Livingston DM, Kaelin WG Jr. Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev. 1992;6:953–64.
pubmed: 1534305
doi: 10.1101/gad.6.6.953
Tarasov KV, Tarasova YS, Tam WL, Riordon DR, Elliott ST, Kania G, et al. B-MYB is essential for normal cell cycle progression and chromosomal stability of embryonic stem cells. PLoS ONE. 2008;3:e2478.
pubmed: 18575582
pmcid: 2423619
doi: 10.1371/journal.pone.0002478
Müller GA, Engeland K. DNA affinity purification: a pulldown assay for identifying and analyzing proteins binding to nucleic acids. Methods Mol Biol. 2021;2267:81–90.
pubmed: 33786786
doi: 10.1007/978-1-0716-1217-0_6
Fischer M, Quaas M, Wintsche A, Müller GA, Engeland K. Polo-like kinase 4 transcription is activated via CRE and NRF1 elements, repressed by DREAM through CDE/CHR sites and deregulated by HPV E7 protein. Nucleic Acids Res. 2014;42:163–80.
pubmed: 24071582
doi: 10.1093/nar/gkt849
Jaber S, Toufektchan E, Lejour V, Bardot B, Toledo F. p53 downregulates the Fanconi anaemia DNA repair pathway. Nat Commun. 2016;7:11091.
pubmed: 27033104
pmcid: 4821997
doi: 10.1038/ncomms11091
Leone G, Nuckolls F, Ishida S, Adams M, Sears R, Jakoi L, et al. Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins. Mol Cell Biol. 2000;20:3626–32.
pubmed: 10779352
pmcid: 85655
doi: 10.1128/MCB.20.10.3626-3632.2000
Fischer M, Grundke I, Sohr S, Quaas M, Hoffmann S, Knörck A, et al. p53 and cell cycle dependent transcription of kinesin family member 23 (KIF23) is controlled via a CHR promoter element bound by DREAM and MMB complexes. PLoS ONE. 2013;8:e63187.
pubmed: 23650552
pmcid: 3641139
doi: 10.1371/journal.pone.0063187
Zheng N, Fraenkel E, Pabo CO, Pavletich NP. Structural basis of DNA recognition by the heterodimeric cell cycle transcription factor E2F-DP. Genes Dev. 1999;13:666–74.
pubmed: 10090723
pmcid: 316551
doi: 10.1101/gad.13.6.666
Mantovani R. A survey of 178 NF-Y binding CCAAT boxes. Nucleic Acids Res. 1998;26:1135–43.
pubmed: 9469818
pmcid: 147377
doi: 10.1093/nar/26.5.1135
Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934–7.
pubmed: 2537532
doi: 10.1126/science.2537532
Fischer M, Uxa S, Stanko C, Magin TM, Engeland K. Human papilloma virus E7 oncoprotein abrogates the p53-p21-DREAM pathway. Sci Rep. 2017;7:2603.
pubmed: 28572607
pmcid: 5453983
doi: 10.1038/s41598-017-02831-9
Enache OM, Rendo V, Abdusamad M, Lam D, Davison D, Pal S, et al. Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nat Genet. 2020;52:662–8.
pubmed: 32424350
pmcid: 7343612
doi: 10.1038/s41588-020-0623-4
Chestukhin A, Litovchick L, Rudich K, DeCaprio JA. Nucleocytoplasmic shuttling of p130/RBL2: novel regulatory mechanism. Mol Cell Biol. 2002;22:453–68.
pubmed: 11756542
pmcid: 139733
doi: 10.1128/MCB.22.2.453-468.2002
Sasaki K, Murakami T, Kawasaki M, Takahashi M. The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Physiol. 1987;133:579–84.
pubmed: 3121642
doi: 10.1002/jcp.1041330321
Miller I, Min M, Yang C, Tian C, Gookin S, Carter D, et al. Ki67 is a graded rather than a binary marker of proliferation versus quiescence. Cell Rep. 2018;24:1105–12.
pubmed: 30067968
pmcid: 6108547
doi: 10.1016/j.celrep.2018.06.110
Schmit F, Cremer S, Gaubatz S. LIN54 is an essential core subunit of the DREAM/LINC complex that binds to the cdc2 promoter in a sequence-specific manner. FEBS J. 2009;276:5703-16.
Marceau AH, Felthousen JG, Goetsch PD, Iness AN, Lee HW, Tripathi SM, et al. Structural basis for LIN54 recognition of CHR elements in cell cycle-regulated promoters. Nat Commun. 2016;7:12301.
pubmed: 27465258
pmcid: 4974476
doi: 10.1038/ncomms12301
Zhang Z, Tu K, Liu F, Liang M, Yu K, Wang Y, et al. FoxM1 promotes the migration of ovarian cancer cell through KRT5 and KRT7. Gene 2020;757:144947.
pubmed: 32659254
doi: 10.1016/j.gene.2020.144947
Tschöp K, Conery AR, Litovchick L, DeCaprio JA, Settleman J, Harlow E, et al. A kinase shRNA screen links LATS2 and the pRB tumor suppressor. Genes Dev. 2011;25:814–30.
pubmed: 21498571
pmcid: 3078707
doi: 10.1101/gad.2000211
Fischer M, Grossmann P, Padi M, DeCaprio JA. Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks. Nucleic Acids Res 2016;44:6070–86.
pubmed: 27280975
pmcid: 4994865
doi: 10.1093/nar/gkw523
Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA, et al. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev. 2002;16:245–56.
pubmed: 11799067
pmcid: 155321
doi: 10.1101/gad.949802
Guiley KZ, Liban TJ, Felthousen JG, Ramanan P, Litovchick L, Rubin SM. Structural mechanisms of DREAM complex assembly and regulation. Genes Dev. 2015;29:961–74.
pubmed: 25917549
pmcid: 4421984
doi: 10.1101/gad.257568.114
Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009;9:749–58.
pubmed: 19776744
pmcid: 2771725
doi: 10.1038/nrc2723
Wang MJ, Pei DS, Qian GW, Yin XX, Cheng Q, Li LT, et al. p53 regulates Ki-67 promoter activity through p53- and Sp1-dependent manner in HeLa cells. Tumour Biol. 2011;32:905–12.
pubmed: 21611785
doi: 10.1007/s13277-011-0191-4
Beijersbergen RL, Carlee L, Kerkhoven RM, Bernards R. Regulation of the retinoblastoma protein-related p107 by G1 cyclin complexes. Genes Dev. 1995;9:1340–53.
pubmed: 7797074
doi: 10.1101/gad.9.11.1340
Bruce JL, Hurford RK Jr., Classon M, Koh J, Dyson N. Requirements for cell cycle arrest by p16INK4a. Mol Cell. 2000;6:737–42.
pubmed: 11030353
doi: 10.1016/S1097-2765(00)00072-1
O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13:417–30.
pubmed: 27030077
doi: 10.1038/nrclinonc.2016.26
Hurvitz SA, Martin M, Press MF, Chan D, Fernandez-Abad M, Petru E, et al. Potent cell-cycle inhibition and upregulation of immune response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR(+)/HER2(-) breast cancer. Clin Cancer Res. 2020;26:566–80.
pubmed: 31615937
doi: 10.1158/1078-0432.CCR-19-1425